Friday, January 21, 2022, San Francisco, California, 6:15 PM – 7:45 PM Pacific Time (9:15 PM – 10:45 PM Eastern Time)

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Hepatobiliary Cancers

Part 3 of a 3-Part CME Symposium Series Held in Conjunction with the 2022 Gastrointestinal Cancers Symposium

Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Program Schedule — Pacific Time
6:00 PM – 6:15 PM — Registration
6:15 PM – 7:45 PM — Educational Dinner Meeting

Meeting Room
Golden Gate Ballroom - Salon A (B2 Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Francisco, CA, preregistration is required as seating is limited.  
 
Faculty
Ghassan Abou-Alfa, MD, MBA
Professor
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Richard S Finn, MD
Professor, Department of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California


Robin K Kelley, MD
Associate Professor of Clinical Medicine
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Moderator
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Consultant, Mayo Clinic in Arizona
Chair, ACCRU Research Consortium
Phoenix, Arizona


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Incyte Corporation and Zymeworks Inc.
Program Schedule — Pacific Time
6:00 PM – 6:15 PM — Registration
6:15 PM – 7:45 PM — Educational Dinner Meeting

MODULE 1: Advances in First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

MODULE 2: Selection and Sequencing of Therapy for Patients with Relapsed/Refractory HCC

MODULE 3: New Directions in the Management of Earlier-Stage HCC

MODULE 4: Novel Treatment Strategies for Advanced Biliary Tract Cancers

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider patient age, performance status, degree of liver function and other clinical and logistical factors in the selection of first- and later-line therapy for unresectable or metastatic hepatocellular carcinoma (HCC).
  • Appreciate Phase III data leading to the FDA approval of novel first-line treatment strategies for unresectable or metastatic HCC, and discuss how these strategies can be optimally integrated into patient care.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with progressive HCC.
  • Maintain an understanding of the side effects and toxicities associated with targeted agents and immunotherapeutic approaches used in the management of advanced HCC, and intervene with early and effective responses to various adverse events.
  • Recognize the molecular heterogeneity of cholangiocarcinomas, and appreciate the biologic rationale for efforts to exploit documented genetic abnormalities in patients with this disease.
  • Assess key data sets supporting the recent FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement, and consider how these agents can be appropriately and safely integrated into clinical management algorithms.
  • Develop an understanding of available clinical trial findings with isocitrate dehydrogenase 1 (IDH1) inhibitors for patients with advanced cholangiocarcinoma and an IDH1 mutation, and identify individuals for whom treatment with this novel strategy is warranted.
  • Recall available and emerging data with investigational agents and strategies currently in clinical testing for hepatobiliary cancers, and where applicable, refer eligible patients for trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Incyte Corporation and Zymeworks Inc.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room
Golden Gate Ballroom - Salon A (B2 Level)

Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Convention Center where the 2022 Gastrointestinal Cancers Symposium is taking place.

 
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

There is no fee to participate in this program or live webcast of this event.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live broadcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not official events of the 2022 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.